Novartis

Novartis trial failure puts pressure on its growth strategy

Novartis shares fell sharply after a clinical trial failure involving a muscle-disorder treatment acquired through Avidity Biosciences. The report should assess what the setback means for investor confidence, Novartis’s pipeline strategy and the wider risks of pharmaceutical acquisitions.